Building a safe dosing routine The best protection against dosing errors is a consistent routine that removes as many variables as possible
In December 2025, the FDA approved the Wegovy pill form, providing an oral semaglutide option for those avoiding injections
Conclusion Concerns about Hims' GLP-1 strategy appear largely overblown The company is likely operating within legal boundaries and has a strong legal team Even if Novo sued for patent infringement, the most likely outcome would be a settlement with minimal negative impact In sum, it appears that concerns over the decision by Hims to continue to compound personalized versions of GLP-1 weight loss drugs past the enforcement deadlines set by the FDA are misplaced
Some people want to raise their IGF-1 levels because certain studies have suggested it may boost longevity and improve body composition
Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist licensed in the UK for treating type 2 diabetes mellitus in adults
The cause of non-alcoholic fatty liver disease (NAFLD), or metabolic dysfunction-associated steatotic liver disease, is still being studied, but someones family history, diet, and personal health history can affect the risk of developing this condition